Major M&A deals impacting bioanalysis in 2025
The first half of 2025 has brought a wave of mergers and acquisitions (M&A) that are reshaping the pharma and biotech landscape. With innovation accelerating and competition intensifying, major players are doubling down on strategic deals to gain access to novel therapies, platforms and technologies. From cancer and neuroscience breakthroughs to bioprocessing tools and diagnostics, these deals reflect a clear trend: big pharma and investors are not waiting for organic growth–they’re buying their way into the future. Below, we break down the most impactful M&A deals and activity so far this year, and what they mean for the industry. Please...
